SCHEMBL7335296

SCHEMBL7335296

NN=Cc1ccc2cc(C(=O)Nc3nccs3)ccc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.66
NPC1 O15118 10/20 0.66
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
MAPK1 P28482 3/20 0.56
PIK3CD O00329 1/20 0.56
PIK3C2B O00750 1/20 0.56
AURKA O14965 1/20 0.56
PIK3C2G O75747 1/20 0.56
CDK1 P06493 1/20 0.56
CDK4 P11802 1/20 0.56
CCND1 P24385 1/20 0.56
CDK2 P24941 1/20 0.56
MAPK3 P27361 1/20 0.56
CCND3 P30281 1/20 0.56
MAPK4 P31152 1/20 0.56
PIK3CA P42336 1/20 0.56
PIK3CB P42338 1/20 0.56
PIK3CG P48736 1/20 0.56
CDK8 P49336 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963854 0.85 RAB9A (0.89) RAB9ANPC1MEN1KMT2AMAPK1
SCHEMBL7343154 0.81 MAPT (0.60) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL7401550 0.80 CSNK2A2 (0.42) RAB9ANPC1MEN1KMT2ACDK2
SCHEMBL7335284 0.79 RAB9A (0.74) RAB9ANPC1MEN1KMT2AMAPK1
SCHEMBL7346861 0.77 SIRT2 (0.53) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL7345841 0.75 ALDH1A1 (0.53) RAB9ANPC1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL7346207 0.75 BCAT2 (0.47) RAB9ANPC1ESR2
SCHEMBL7340325 0.74 GRM5 (0.56) RAB9ANPC1SMN1; SMN2LMNAMAPT
SCHEMBL7341819 0.74 SIRT2 (0.54) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL6593539 0.74 RAB9A (0.68) RAB9ANPC1MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 RAB9A 2845/4885NPC1 2478/4885MEN1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.